Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – HC Wainwright issued their FY2029 EPS estimates for Merus Labs International in a report released on Thursday, March 27th. HC Wainwright analyst A. He forecasts that the specialty pharmaceutical company will earn ($0.13) per share for the year.
Merus Labs International Stock Performance
The business’s fifty day moving average is C$1.65. Merus Labs International has a one year low of C$0.95 and a one year high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- MarketBeat Week in Review – 03/24 – 03/28
- What is the Shanghai Stock Exchange Composite Index?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Where to Find Earnings Call Transcripts
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
